Invitae Akcie

Invitae Dluh/EBITDA

Delisted·7. 8. 2024

Poměr Celkového Dluhu k EBITDA společnosti Invitae (NVTAQ) k datu 14. 8. 2026.

Dluh/EBITDA

0,00

Poslední aktualizace:

Poměr Celkového Dluhu k EBITDA společnosti Invitae je 2026 0,00 . Poměr Celkového Dluhu k EBITDA společnosti Invitae byl 2025 -2,27 . Klesá tak o % vyšší než v předchozím roce.
Access this data via the Eulerpool API

Invitae Analýza akcií

Co dělá Invitae? Invitae Corp is a US-based company specialized in providing genetic tests for the diagnosis, treatment, and prevention of diseases. It was founded in 2010 and is headquartered in San Francisco, California. The company's goal is to lower the cost of genetic testing and increase accessibility for patients through automation and sample pooling methods. Invitae has received significant funding and has expanded its capital through multiple rounds of investments from venture capital firms, totaling nearly half a billion dollars. Its business model focuses on offering genetic tests to a wide range of patient groups, streamlining the testing processes through automation and software optimization. Invitae serves consumers directly, as well as medical professionals, hospitals, health centers, laboratories, and health insurance companies. The company aims to improve disease diagnosis and early detection while promoting long-term patient health. Invitae has broadened its capabilities through strategic acquisitions and partnerships, consolidating genetic data on a single platform. It offers a diverse portfolio of genetic tests for the diagnosis, treatment, and prevention of various diseases, including cancer predisposition, cardiovascular diseases, rare inherited diseases, neurological disorders, and medical genomics. The company also provides genetic counseling and family-oriented diagnosis services, along with an online platform facilitating interactive communication between doctors and patients, enabling the sharing and presentation of genetic information and test results. Invitae is an innovative company that has established itself as a market leader in genetic testing, offering a wide range of products and services facilitated by advanced technologies and data storage solutions. The recent acquisitions and partnerships have expanded Invitae's portfolio, improved its technology platform, and strengthened its position as a provider of high-quality healthcare services, enabling well-informed decision-making for patients and medical professionals. Invitae je jednou z nejoblíbenějších společností na Eulerpool.com.

Často kladené otázky ohledně akcií Invitae

Na Eulerpool najdete úplný historický vývoj Poměr Celkového Dluhu k EBITDA Invitae od roku 2006 – s ročními hodnotami, grafy a podrobnou analýzou.

Dluh/EBITDA měří celkový dluh v poměru k zisku před úroky, daněmi a odpisy. Ukazuje roky potřebné k splacení veškerého dluhu z EBITDA.

Dobrá hodnota se liší podle odvětví a fáze vývoje společnosti. Na Eulerpool můžete porovnat Invitae společnosti Poměr Celkového Dluhu k EBITDA s porovnatelnými společnostmi a průměrem odvětví, abyste určili, zda je atraktivní.

Access this data via the Eulerpool API

Páka — Invitae

Všechny klíčové ukazatele — Invitae